{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:58:47Z","timestamp":1787741927304,"version":"build-2784847793"},"reference-count":56,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,9,16]],"date-time":"2013-09-16T00:00:00Z","timestamp":1379289600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabet. Med."],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>Recent suggestions that glucagon\u2010like peptide\u20101 (GLP\u20101)\u2010based therapies could cause pancreatitis, and even pancreatic cancer, are based on:<\/jats:p><\/jats:sec><jats:sec><jats:title>Animal studies<\/jats:title><jats:p>The worrying histological changes are not reproduced in all studies and are unexpectedly variable with different GLP\u20101\u2010based therapies.<\/jats:p><\/jats:sec><jats:sec><jats:title>An observational study<\/jats:title><jats:p>Singh's findings that pancreatitis is doubled with GLP\u20101\u2010based therapies could relate to their use in obese patients who are prone to pancreatitis risk factors\u2014gallstones and hypertriglyceridaemia. The other observational studies do not find an association between GLP\u20101\u2010based therapies and pancreatitis.<\/jats:p><\/jats:sec><jats:sec><jats:title>US Food and Drug Administration adverse event reporting system<\/jats:title><jats:p>The increased reports of pancreatitis and pancreatic cancer are likely to be attributable to \u2018notoriety bias\u2019.<\/jats:p><\/jats:sec><jats:sec><jats:title>A study of organ donor pancreases<\/jats:title><jats:p>Butler's findings for those on GLP\u20101\u2010based therapies vs. those not, could have other explanations. Meanwhile:<\/jats:p><\/jats:sec><jats:sec><jats:title>Meta analysis<\/jats:title><jats:p>Randomized control trials with GLP\u20101\u2010based therapies do not find increased pancreatitis risk. Meta\u2010analysis of 53 randomized controlled trials including 20\u00a0212 dipeptidyl peptidase\u20104 inhibitor\u2010treated patients found a significantly reduced risk of major adverse cardiovascular events [odds ratio\u00a00.689 (0.528\u20130.899), <jats:italic>P<\/jats:italic>\u00a0=\u00a00.006] for dipeptidyl peptidase\u20104 inhibitors compared with control subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Cardiovascular risk<\/jats:title><jats:p>The evidence suggests that there is more than a possibility that some of the GLP\u20101 receptor agonists, and possibly also some dipeptidyl peptidase\u20104 inhibitors, may be associated with reduced cardiovascular events. Eight ongoing long\u2010term cardiovascular randomized controlled trials will report from September 2013 onwards. These trials should resolve the issue of pancreatitis risk and substantiate the extent of benefit.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Whilst we should remain vigilant, currently the balance of evidence is strongly in support of GLP\u20101\u2010based therapy, with benefits far outweighing potential risks.<\/jats:p><\/jats:sec>","DOI":"10.1111\/dme.12301","type":"journal-article","created":{"date-parts":[[2014,8,18]],"date-time":"2014-08-18T05:05:28Z","timestamp":1408338328000},"page":"1148-1155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["The potential risks of pancreatitis and pancreatic cancer with GLP\u20101\u2010based therapies are far outweighed by the proven and potential (cardiovascular) benefits"],"prefix":"10.1111","volume":"30","author":[{"given":"R. E. J.","family":"Ryder","sequence":"first","affiliation":[{"name":"Department of Diabetes and Endocrinology City Hospital Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,16]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.2720"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f1263"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/db12-1686"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2713"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3680"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3617"},{"key":"e_1_2_12_8_1","unstructured":"Channel\u00a04 UK.Diets Drugs and Diabetes. A \u2018Dispatches current affairs programme\u2019 screened on British television's Channel\u00a04 at 20.00\u00a0h on 10 June 2013."},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3819"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3692"},{"key":"e_1_2_12_11_1","unstructured":"Institute for Safe Medication Practices.Perspectives on GLP\u20101 Agents for Diabetes.2013. Available atwww.ismp.org\/QuarterWatch\/pdfs\/2012Q3.pdfLast accessed 30 June 2013."},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.02.018"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.829176"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.1322"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e3182009701"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-2504"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02382.x"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0058"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2010.02.003"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)32155-6"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00534-005-1047-3"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990902820519"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0482"},{"key":"e_1_2_12_24_1","first-page":"A160","article-title":"Association between diabetes, exenatide, sitagliptin and acute pancreatitis","volume":"59","author":"Pendergrass M","year":"2010","journal-title":"Diabetes"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2011.01376.x"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.2012.03652.x"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2267"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/pdi.1522"},{"key":"e_1_2_12_29_1","first-page":"49","volume-title":"Hot topics in diabetes","author":"Ryder B","year":"2012"},{"key":"e_1_2_12_30_1","doi-asserted-by":"crossref","unstructured":"RyderREJ ThongKY BlannA PhillipsS BarwellN KellyCet al.Liraglutide and acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide liraglutide audit. Poster 15 (late breaking) ABCD Spring Meeting Solihull UK 18\u201319 April 2013. Available athttp:\/\/www.diabetologists-abcd.org.uk\/GLP1_Audits\/Liraglutide_Pancreatitis_Poster_ABCD_Apr2013.pdfLast accessed 30 June 2013.","DOI":"10.1002\/pdi.1748"},{"key":"e_1_2_12_31_1","doi-asserted-by":"crossref","unstructured":"RyderREJ ThongKY on behalf of the ABCD nationwide exenatide audit contributors.Incidence of acute pancreatitis in the Association of British Clinical Diabetologists (ABCD) nationwide exenatide audit.2013. Available athttp:\/\/www.diabetologists-abcd.org.uk\/GLP1_Audits\/pancreatitis_incidence_exenatide_audit.pdfLast accessed 30 June 2013.","DOI":"10.1002\/pdi.1748"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f2607"},{"key":"e_1_2_12_33_1","first-page":"1","article-title":"The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database","author":"Raschi E","year":"2011","journal-title":"Acta Diabetol"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.2337\/db13-0520"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6823-10-20"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f4382"},{"key":"e_1_2_12_37_1","first-page":"57","article-title":"Glucagon\u2010like peptide\u20101 receptor agonists and cardiovascular events: a meta\u2010analysis of randomized clinical trials","volume":"27","author":"Monami M","year":"2011","journal-title":"Exp Diabetes Res"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.405"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.54.1.146"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sus001"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1185\/030079908X253870"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2361"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-12-48"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2840-10-22"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02495.x"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.2217\/clp.13.8"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1177\/1479164111408937"},{"key":"e_1_2_12_48_1","unstructured":"European Medicines Agency.Lyxumia. Summary of Product Characterisics.2013. Available athttp:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002445\/WC500140401.pdfLast accessed 30 June 2013."},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-84"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2011.08.001"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/sus003"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2012.01674.x"},{"key":"e_1_2_12_53_1","unstructured":"Bristol\u2010Myers Squibb.AstraZeneca and Bristol\u2010Myers Squibb Announce Top Line Results for SAVOR\u2010TIMI\u201053 Cardiovascular Outcomes Trial of Onglyza\u00ae(saxagliptin).2013. Available athttp:\/\/m.news.bms.com\/press-release\/astrazeneca-and-bristol-myers-squibb-announce-top-line-results-savor-timi-53-cardiovasLast accessed 20 June 2013."},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.08.006"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2011.08.004"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889"}],"updated-by":[{"DOI":"10.1111\/dme.12350","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2013,11,17]],"date-time":"2013-11-17T00:00:00Z","timestamp":1384646400000}}],"container-title":["Diabetic Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fdme.12301","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/dme.12301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T06:35:02Z","timestamp":1696314902000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/dme.12301"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,16]]},"references-count":56,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/dme.12301"],"URL":"https:\/\/doi.org\/10.1111\/dme.12301","archive":["Portico"],"relation":{},"ISSN":["0742-3071","1464-5491"],"issn-type":[{"value":"0742-3071","type":"print"},{"value":"1464-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,16]]},"assertion":[{"value":"2013-07-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-08-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}